<DOC>
	<DOCNO>NCT01504581</DOCNO>
	<brief_summary>Study design : This randomize , double-blind , placebo- active-controlled , single-dose study 4 group 12 healthy male subject . In group , 8 subject receive dose HM10660A , 2 subject receive single dose placebo 2 subject receive single dose currently market PEG-interferon .</brief_summary>
	<brief_title>Safety , Pharmacokinetic , Pharmacodynamic Study LAPS-IFNa Healthy Adult Subjects</brief_title>
	<detailed_description>Primary objective : study safety tolerability HM10660A , include immunogenicity , compare PEG-interferon alpha-2a Secondary objective : study pharmacokinetics pharmacodynamics HM10660A compare PEG-interferon alpha-2a</detailed_description>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Age : 18 45 Years , Inclusive BMI : 18.0 28.0 kg/m2 Are Nonsmokers Smoker Fewer Than 5 Cigarettes Per Day Determined History Mental Handicap Evidence Clinically Relevant Pathology History Type 1 Diabetes Thyroid Disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>